Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Impact · against what's priced in

The positive CHMP opinion for RASONQUE in the EU provides a modest catalyst by opening a new geographic revenue stream, but the core clinical value is already reflected in the stock price. Because the market already assumes the drug's efficacy in pancreatic cancer, the impact is limited to the timing of international commercialization.

RVMD+0.30

Not in the price yet

The price assumes

Daraxonrasib commercial launch in pancreatic adenocarcinoma